Hospira's biosimilar set to replace Remicade to treat inflammation in Australia
Hospira (NYSE: HSP) announced it has registered biosimilar Inflectra (infliximab) to treat inflammatory conditions in Australia.
The move is in line with the Australian government’s bid to cut the cost of some of the expensive drugs under the Pharmaceutical Benefits Scheme (PBS). Inflectra will replace the biologic Remicade (infliximab) from Merck & Co, which cost the PBS more than A$100 million last year. A biosimilar has the potential to deliver a 20-30% reduction in the price paid for the therapy.
The maker of injectable drugs, which is the subject of an agreed $17 billion takeover by Pfizer (NYSE: PFE), said the biosimilar will treat eight inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis (AS), and adult and pediatric Crohn's disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze